CELU vs. INMB, MDWD, CTNM, FULC, MOLN, CGEN, PLX, PRQR, INBX, and CYBN
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include INmune Bio (INMB), MediWound (MDWD), Contineum Therapeutics (CTNM), Fulcrum Therapeutics (FULC), Molecular Partners (MOLN), Compugen (CGEN), Protalix BioTherapeutics (PLX), ProQR Therapeutics (PRQR), Inhibrx (INBX), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry.
Celularity vs.
INmune Bio (NASDAQ:INMB) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.
12.7% of INmune Bio shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 35.2% of INmune Bio shares are held by company insiders. Comparatively, 22.1% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
INmune Bio has a net margin of 0.00% compared to Celularity's net margin of -72.72%. INmune Bio's return on equity of -117.48% beat Celularity's return on equity.
INmune Bio has higher earnings, but lower revenue than Celularity.
INmune Bio has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
In the previous week, INmune Bio had 5 more articles in the media than Celularity. MarketBeat recorded 5 mentions for INmune Bio and 0 mentions for Celularity. INmune Bio's average media sentiment score of 1.00 beat Celularity's score of 0.00 indicating that INmune Bio is being referred to more favorably in the media.
INmune Bio presently has a consensus price target of $22.80, suggesting a potential upside of 165.42%. Given INmune Bio's stronger consensus rating and higher possible upside, research analysts clearly believe INmune Bio is more favorable than Celularity.
INmune Bio received 136 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 76.60% of users gave INmune Bio an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Summary
INmune Bio beats Celularity on 14 of the 17 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
This page (NASDAQ:CELU) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CELU Stock Alerts